Cargando…

Novel drug-target interactions via link prediction and network embedding

BACKGROUND: As many interactions between the chemical and genomic space remain undiscovered, computational methods able to identify potential drug-target interactions (DTIs) are employed to accelerate drug discovery and reduce the required cost. Predicting new DTIs can leverage drug repurposing by i...

Descripción completa

Detalles Bibliográficos
Autores principales: Amiri Souri, E., Laddach, R., Karagiannis, S. N., Papageorgiou, L. G., Tsoka, S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978405/
https://www.ncbi.nlm.nih.gov/pubmed/35379165
http://dx.doi.org/10.1186/s12859-022-04650-w
_version_ 1784680957137125376
author Amiri Souri, E.
Laddach, R.
Karagiannis, S. N.
Papageorgiou, L. G.
Tsoka, S.
author_facet Amiri Souri, E.
Laddach, R.
Karagiannis, S. N.
Papageorgiou, L. G.
Tsoka, S.
author_sort Amiri Souri, E.
collection PubMed
description BACKGROUND: As many interactions between the chemical and genomic space remain undiscovered, computational methods able to identify potential drug-target interactions (DTIs) are employed to accelerate drug discovery and reduce the required cost. Predicting new DTIs can leverage drug repurposing by identifying new targets for approved drugs. However, developing an accurate computational framework that can efficiently incorporate chemical and genomic spaces remains extremely demanding. A key issue is that most DTI predictions suffer from the lack of experimentally validated negative interactions or limited availability of target 3D structures. RESULTS: We report DT2Vec, a pipeline for DTI prediction based on graph embedding and gradient boosted tree classification. It maps drug-drug and protein–protein similarity networks to low-dimensional features and the DTI prediction is formulated as binary classification based on a strategy of concatenating the drug and target embedding vectors as input features. DT2Vec was compared with three top-performing graph similarity-based algorithms on a standard benchmark dataset and achieved competitive results. In order to explore credible novel DTIs, the model was applied to data from the ChEMBL repository that contain experimentally validated positive and negative interactions which yield a strong predictive model. Then, the developed model was applied to all possible unknown DTIs to predict new interactions. The applicability of DT2Vec as an effective method for drug repurposing is discussed through case studies and evaluation of some novel DTI predictions is undertaken using molecular docking. CONCLUSIONS: The proposed method was able to integrate and map chemical and genomic space into low-dimensional dense vectors and showed promising results in predicting novel DTIs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-022-04650-w.
format Online
Article
Text
id pubmed-8978405
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-89784052022-04-05 Novel drug-target interactions via link prediction and network embedding Amiri Souri, E. Laddach, R. Karagiannis, S. N. Papageorgiou, L. G. Tsoka, S. BMC Bioinformatics Research BACKGROUND: As many interactions between the chemical and genomic space remain undiscovered, computational methods able to identify potential drug-target interactions (DTIs) are employed to accelerate drug discovery and reduce the required cost. Predicting new DTIs can leverage drug repurposing by identifying new targets for approved drugs. However, developing an accurate computational framework that can efficiently incorporate chemical and genomic spaces remains extremely demanding. A key issue is that most DTI predictions suffer from the lack of experimentally validated negative interactions or limited availability of target 3D structures. RESULTS: We report DT2Vec, a pipeline for DTI prediction based on graph embedding and gradient boosted tree classification. It maps drug-drug and protein–protein similarity networks to low-dimensional features and the DTI prediction is formulated as binary classification based on a strategy of concatenating the drug and target embedding vectors as input features. DT2Vec was compared with three top-performing graph similarity-based algorithms on a standard benchmark dataset and achieved competitive results. In order to explore credible novel DTIs, the model was applied to data from the ChEMBL repository that contain experimentally validated positive and negative interactions which yield a strong predictive model. Then, the developed model was applied to all possible unknown DTIs to predict new interactions. The applicability of DT2Vec as an effective method for drug repurposing is discussed through case studies and evaluation of some novel DTI predictions is undertaken using molecular docking. CONCLUSIONS: The proposed method was able to integrate and map chemical and genomic space into low-dimensional dense vectors and showed promising results in predicting novel DTIs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12859-022-04650-w. BioMed Central 2022-04-04 /pmc/articles/PMC8978405/ /pubmed/35379165 http://dx.doi.org/10.1186/s12859-022-04650-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Amiri Souri, E.
Laddach, R.
Karagiannis, S. N.
Papageorgiou, L. G.
Tsoka, S.
Novel drug-target interactions via link prediction and network embedding
title Novel drug-target interactions via link prediction and network embedding
title_full Novel drug-target interactions via link prediction and network embedding
title_fullStr Novel drug-target interactions via link prediction and network embedding
title_full_unstemmed Novel drug-target interactions via link prediction and network embedding
title_short Novel drug-target interactions via link prediction and network embedding
title_sort novel drug-target interactions via link prediction and network embedding
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8978405/
https://www.ncbi.nlm.nih.gov/pubmed/35379165
http://dx.doi.org/10.1186/s12859-022-04650-w
work_keys_str_mv AT amirisourie noveldrugtargetinteractionsvialinkpredictionandnetworkembedding
AT laddachr noveldrugtargetinteractionsvialinkpredictionandnetworkembedding
AT karagiannissn noveldrugtargetinteractionsvialinkpredictionandnetworkembedding
AT papageorgioulg noveldrugtargetinteractionsvialinkpredictionandnetworkembedding
AT tsokas noveldrugtargetinteractionsvialinkpredictionandnetworkembedding